Dose finding study with irinotecan (CPT-11) in previously treated colo-rectal cancer

被引：0
|
作者：
Viéitez, JM
Carrasco, J
Fra, J
Muñiz, I
Esteban, E
Palacio, I
Sala, M
Puertas, J
Estrada, E
Buesa, JM
Lacave, AJ
机构：
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S75 / S75
页数：1
相关论文
共 50 条
  • [31] Effect of Irinotecan (CPT-11) on fatty acid status in rats with colorectal cancer
    Krishnamurthi, Veena
    Pawlowicz, Megan
    Xue, Hongyu
    Baracos, Vickie
    Clandinin, M. Thomas
    Mazurak, Vera C.
    FASEB JOURNAL, 2008, 22
  • [32] A phase II study of irinotecan (CPT-11) and carboplatin in patients with previously untreated small cell lung cancer (SCLC):: Preliminary results.
    Amenedo, M
    Vázquez, F
    Lázaro, M
    Casal, J
    Mel, JR
    Antón, LM
    Firvida, JL
    Grande, C
    Castellanos, J
    Balcells, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 687S - 687S
  • [33] Phase II study of weekly irinotecan (CPT-11) associated to protracted oral tegafur (TGF) in previously untreated, advanced colorectal cancer (ACRC)
    Saigi, E
    Batiste-Alentorn, E
    Diaz, N
    Galan, A
    Salud, A
    Campos, JM
    Losa, F
    Gallen, M
    Massuti, B
    Asensio, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 302S - 302S
  • [34] Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma - a feasibility study
    Knuuttila, A
    Ollikainen, T
    Halme, M
    Mali, P
    Kivisaari, L
    Linnainmaa, K
    Jekunen, A
    Mattson, K
    ANTI-CANCER DRUGS, 2000, 11 (04) : 257 - 261
  • [35] Phase I and pharmacokinetic study of irinotecan (CPT-11) administered with cyclosporine A (CSA).
    Fagbemi, S
    Ratain, MJ
    Iyer, L
    Mani, S
    Vogelzang, NJ
    Wang, X
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 163 - 163
  • [36] Phase II study of irinotecan (CPT-11) alone in patients (pts) with metastatic pancreatic cancer.
    Funakoshi, A
    Okusaka, T
    Ishii, H
    Sawaki, A
    Ohkawa, S
    Ishikawa, O
    Saitoh, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 338S - 338S
  • [37] Phase II trial and pharmacokinetic study of irinotecan (CPT-11) in patients with glioblastoma
    Boige, V
    Raymond, E
    Fabbro, M
    Plazza, J
    Vassal, G
    Risse, ML
    Rodier, JM
    Armand, JP
    ANNALS OF ONCOLOGY, 1998, 9 : 137 - 137
  • [38] The current chemotherapy for advanced pancreatic cancer including the result of phase II study of irinotecan (CPT-11)
    Sumii, Toshihiko
    Fujimori, Nao
    Funakoshi, Akihiro
    PANCREAS, 2008, 37 (01) : 112 - 112
  • [39] Phase II study of carboplatin (CBDCA) and irinotecan (CPT-11) for patients with cancer of unknown primary (CUP)
    Ando, M., Sr.
    Yonemori, K.
    Yunokawa, M.
    Nakano, E.
    Kouno, T.
    Shimizu, C.
    Katsumata, N.
    Tamura, K.
    Arioka, H.
    Fujiwara, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] A phase I study of amrubicin (AMR) and irinotecan (CPT-11) in relapsed small cell lung cancer
    Mio, T.
    Kawahara, M.
    Fukushima, M.
    Yanagihara, K.
    Daimon, T.
    Furuse, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345